Personalized medicine in psychiatry: problems and promises

BMC Medicine

Charles BNemeroff¹  Claes Wahlestedt¹  Uzoezi Ozomaro² 

[1] Department of Psychiatry and Behavioral Sciences, University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA;University of Miami, Leonard M. Miller School of Medicine, Miami, FL, USA

关键词: Neuroimaging genetics;    Pharmacogenomics;    Endophenotypes;    Environmental factors;    Epigenetics;    Psychiatric hereditability;    Personalized medicine;    Schizophrenia;    Major depressive disorder;   

Others  :  857025
DOI  :  10.1186/1741-7015-11-132

 received in 2012-09-20, accepted in 2013-04-19,  发布年份 2013

【 摘 要 】

The central theme of personalized medicine is the premise that an individual’s unique physiologic characteristics play a significant role in both disease vulnerability and in response to specific therapies. The major goals of personalized medicine are therefore to predict an individual’s susceptibility to developing an illness, achieve accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging.

【 授权许可】

   
2013 Ozomaro et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Myers AJ, Nemeroff CB: New Vistas in the Management of Treatment-Refractory Psychiatric Disorders: Genomics and Personalized Medicine. Focus 2010, 8:525-535.
• [2]Mehta R, Jain RK, Badve S: Personalized medicine: the road ahead. Clin Breast Cancer 2011, 11:20-26.
• [3]Conneally PM: Huntington disease: genetics and epidemiology. Am J Hum Genet 1984, 36:506-526.
• [4]Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
• [5]Risch SC, Nemeroff CB: Neurochemical alterations of serotonergic neuronal systems in depression. J Clin Psychiatry 1992, 53:3-7.
• [6]Krishnan V, Nestler EJ: The molecular neurobiology of depression. Nature 2008, 455:894-902.
• [7]Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM, Smith CA: Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 1996, 347:731-733.
• [8]Hoefgen B, Schulze TG, Ohlraun S, Von Widdern O, Höfels S, Gross M, Heidmann V, Kovalenko S, Eckermann A, Kölsch H, Metten M, Zobel A, Becker T, Nöthen MM, Propping P, Heun R, Maier W, Rietschel M: The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 2005, 57:247-251.
• [9]Gao J, Pan Z, Jiao Z, Li F, Zhao G, Wei Q, Pan F, Evangelou E: TPH2 Gene Polymorphisms and Major Depression - A Meta-Analysis. PLoS One 2012, 7:e36721.
• [10]Walther DJ, Bader M: A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003, 66:1673-1680.
• [11]Nash MW, Sugden K, Huezo-Diaz P, Williamson R, Sterne A, Purcell S, Sham PC, Craig IW: Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. Am J Med Genet B Neuropsychiatr Genet 2005, 135B:33-37.
• [12]Gizatullin R, Zaboli G, Jönsson EG, Asberg M, Leopardi R: Haplotype analysis reveals tryptophan hydroxylase (TPH) 1 gene variants associated with major depression. Biol Psychiatry 2006, 59:295-300.
• [13]Zill P, Baghai TC, Zwanzger P, Schüle C, Eser D, Rupprecht R, Möller H-J, Bondy B, Ackenheil M: SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 2004, 9:1030-1036.
• [14]Zhang X, Beaulieu J-M, Sotnikova TD, Gainetdinov RR, Caron MG: Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004, 305:217.
• [15]Zhang X, Gainetdinov RR, Beaulieu J-M, Sotnikova TD, Burch LH, Williams RB, Schwartz DA, Krishnan KRR, Caron MG: Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 2005, 45:11-16.
• [16]Garriock HA, Allen JJB, Delgado P, Nahaz Z, Kling MA, Carpenter L, Burke M, Burke W, Schwartz T, Marangell LB, Husain M, Erickson RP, Moreno FA: Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005, 10:976-977.
• [17]Serretti A, Chiesa A, Porcelli S, Han C, Patkar AA, Lee S-J, Park MH, Pae C-U: Influence of TPH2 variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Psychiatry Res 2011, 189:26-32.
• [18]Schuhmacher A, Becker T, Rujescu D, Quednow BB, Lennertz L, Wagner M, Benninghoff J, Rietschel M, Häfner H, Franke P, Wölwer W, Gaebel W, Maier W, Mössner R: Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J Psychiatric Res 2012, 46:1073-1080.
• [19]Zhang C, Li Z, Shao Y, Xie B, Du Y, Fang Y, Yu S: Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci 2011, 43:406-411.
• [20]Kim Y-K, Lee H-J, Yang J-C, Hwang J-A, Yoon H-K: A tryptophan hydroxylase 2 gene polymorphism is associated with panic disorder. Behav Genet 2009, 39:170-175.
• [21]Mössner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, Bogusch L, Remschmidt H, Simons M, Herpertz-Dahlmann B, Fleischhaker C, Schulz E, Warnke A, Hinney A, Wewetzer C, Lesch K-P: Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2006, 9:437-442.
• [22]Walitza S, Renner TJ, Dempfle A, Konrad K, Wewetzer C, Halbach A, Herpertz-Dahlmann B, Remschmidt H, Smidt J, Linder M, Flierl L, Knölker U, Friedel S, Schäfer H, Gross C, Hebebrand J, Warnke A, Lesch KP: Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 2005, 10:1126-1132.
• [23]Nemeroff CB: Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. J Clin Psychiatry 1989, 50:13-20. discussion 21–22
• [24]Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Pütz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Künzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Köhnlein O, Dabitz H, Brückl T, Müller N, Pfister H, Lieb R: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319-1325.
• [25]Tatro ET, Everall IP, Masliah E, Hult BJ, Lucero G, Chana G, Soontornniyomkij V, Achim CL: Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 2009, 4:218-226.
• [26]Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N, Vitiello B, Birmaher B, Mayes T, Zelazny J, Onorato M, Devlin B, Clarke G, DeBar L, Keller M: Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study. Am J Psychiatry 2010, 167:190-197.
• [27]Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK, Blanquet V, Steckler T, Holsboer F, Wurst W: Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998, 19:162-166.
• [28]Gillespie CF, Binder EB, Holtzheimer PE, Nemeroff CB: Stress and the impact of personalized medicine. In Integrative Neuroscience and Personalized Medicine. Oxford: Oxford University Press; 2010:73-92.
• [29]Hartline KM, Owens MJ, Nemeroff CB: Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans. Ann N Y Acad Sci 1996, 780:96-105.
• [30]Arató M, Bánki CM, Bissette G, Nemeroff CB: Elevated CSF CRF in suicide victims. Biol Psychiatry 1989, 25:355-359.
• [31]Nemeroff CB, Widerlöv E, Bissette G, Walléus H, Karlsson I, Eklund K, Kilts CD, Loosen PT, Vale W: Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
• [32]Liu Z, Zhu F, Wang G, Xiao Z, Wang H, Tang J, Wang X, Qiu D, Liu W, Cao Z, Li W: Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett 2006, 404:358-362.
• [33]Papiol S, Arias B, Gastó C, Gutiérrez B, Catalán R, Fañanás L: Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007, 104:83-90.
• [34]Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJM, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S: The FKBP5-gene in depression and treatment response–an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008, 63:1103-1110.
• [35]Claes S, Villafuerte S, Forsgren T, Sluijs S, Del-Favero J, Adolfsson R, Van Broeckhoven C: The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden. Biol Psychiatry 2003, 54:867-872.
• [36]Van Den Eede F, Venken T, Del-Favero J, Norrback K-F, Souery D, Nilsson LG, Van den Bossche B, Hulstijn W, Sabbe BGC, Cosyns P, Mendlewicz J, Adolfsson R, Van Broeckhoven C, Claes SJ: Single nucleotide polymorphism analysis of corticotropin-releasing factor-binding protein gene in recurrent major depressive disorder. Psychiatry Res 2007, 153:17-25.
• [37]Smoller JW, Finn CT: Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003, 123C:48-58.
• [38]Barnett JH, Smoller JW: The genetics of bipolar disorder. Neuroscience 2009, 164:331-343.
• [39]Craddock N, Sklar P: Genetics of bipolar disorder: successful start to a long journey. Trends Genet 2009, 25:99-105.
• [40]Willour VL, Chen H, Toolan J, Belmonte P, Cutler DJ, Goes FS, Zandi PP, Lee RS, MacKinnon DF, Mondimore FM, Schweizer B, DePaulo JR Jr, Gershon ES, McMahon FJ, Potash JB: Family-based association of FKBP5 in bipolar disorder. Mol Psychiatry 2009, 14:261-268.
• [41]Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang K-Y, Huganir RL, Valle D, Pulver AE: Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005, 77:918-936.
• [42]Gawlik M, Moller-Ehrlich K, Mende M, Jovnerovski M, Jung S, Jabs B, Knapp M, Stoeber G: Is FKBP5 a genetic marker of affective psychosis? A case control study and analysis of disease related traits. BMC Psychiatry 2006, 6:52.
• [43]Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
• [44]Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ: A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008, 13:197-207.
• [45]Benedetti F, Serretti A, Colombo C, Barbini B, Lorenzi C, Campori E, Smeraldi E: Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2003, 123B:23-26.
• [46]Shi J, Wittke-Thompson JK, Badner JA, Hattori E, Potash JB, Willour VL, McMahon FJ, Gershon ES, Liu C: Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1047-1055.
• [47]Wager-Smith K, Kay SA: Circadian rhythm genetics: from flies to mice to humans. Nat Genet 2000, 26:23-27.
• [48]Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin B, Nimgaonkar VL: Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav 2006, 5:150-157.
• [49]Ferreira MAR, O’Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M: Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008, 40:1056-1058.
• [50]Cichon S, Mühleisen TW, Degenhardt FA, Mattheisen M, Miró X, Strohmaier J, Steffens M, Meesters C, Herms S, Weingarten M, Priebe L, Haenisch B, Alexander M, Vollmer J, Breuer R, Schmäl C, Tessmann P, Moebus S, Wichmann H-E, Schreiber S, Müller-Myhsok B, Lucae S, Jamain S, Leboyer M, Bellivier F, Etain B, Henry C, Kahn J-P, Heath S, Hamshere M: Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet 2011, 88:372-381.
• [51]Sklar P, Ripke S, Scott LJ: Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011, 43:977-983.
• [52]Green EK, Grozeva D, Forty L, Gordon-Smith K, Russell E, Farmer A, Hamshere M, Jones IR, Jones L, McGuffin P, Moran JL, Purcell S, Sklar P, Owen MJ, O’Donovan MC, Craddock N: Association at SYNE1 in both bipolar disorder and recurrent major depression. Mol Psychiatry 2012, 18:614-617.
• [53]Warren DT, Zhang Q, Weissberg PL, Shanahan CM: Nesprins: intracellular scaffolds that maintain cell architecture and coordinate cell function? Expert Rev Mol Med 2005, 7:1-15.
• [54]Cardno AG, Marshall EJ, Coid B, Macdonald AM, Ribchester TR, Davies NJ, Venturi P, Jones LA, Lewis SW, Sham PC, Gottesman II, Farmer AE, McGuffin P, Reveley AM, Murray RM: Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999, 56:162-168.
• [55]Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am J Med Genet 2000, 97:12-17.
• [56]Gejman PV, Sanders AR, Kendler KS: Genetics of schizophrenia: new findings and challenges. Annu Rev Genomics Hum Genet 2011, 12:121-144.
• [57]Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
• [58]Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV: Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009, 460:753-757.
• [59]Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OPH, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller H-J, Giegling I: Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
• [60]O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CCA, Howie B, Leung H-T, Hartmann AM, Möller H-J, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Cichon S, Nöthen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008, 40:1053-1055.
• [61]Riley B, Thiselton D, Maher BS, Bigdeli T, Wormley B, McMichael GO, Fanous AH, Vladimirov V, O’Neill FA, Walsh D, Kendler KS: Replication of association between schizophrenia and ZNF804A in the Irish Case–control Study of Schizophrenia sample. Mol Psychiatry 2010, 15:29-37.
• [62]Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OPH, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jürgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Möller H-J, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Réthelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K: Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry 2011, 16:59-66.
• [63]Zhang R, Lu SM, Qiu C, Liu XG, Gao CG, Guo TW, Valenzuela RK, Deng HW, Ma J: Population-based and family-based association studies of ZNF804A locus and schizophrenia. Mol Psychiatry 2011, 16:360-361.
• [64]Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007, 12:572-580.
• [65]Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O’Donovan MC: Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011, 16:429-441.
• [66]Flora A, Garcia JJ, Thaller C, Zoghbi HY: The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc Natl Acad Sci USA 2007, 104:15382-15387.
• [67]De Pontual L, Mathieu Y, Golzio C, Rio M, Malan V, Boddaert N, Soufflet C, Picard C, Durandy A, Dobbie A, Heron D, Isidor B, Motte J, Newburry-Ecob R, Pasquier L, Tardieu M, Viot G, Jaubert F, Munnich A, Colleaux L, Vekemans M, Etchevers H, Lyonnet S, Amiel J: Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndrome. Hum Mutat 2009, 30:669-676.
• [68]Pitt D, Hopkins I: A syndrome of mental retardation, wide mouth and intermittent overbreathing. Aust Paediatr J 1978, 14:182-184.
• [69]Steinberg S, De Jong S, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OPH, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lönnqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E, Jürgens G, Glenthøj B, Terenius L: Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet 2011, 20:4076-4081.
• [70]Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin D, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood D, Pato CN, Malhotra AK, Purcell SM, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous AH, Stefansson H, Steinberg S: Genome-wide association study identifies five new schizophrenia loci. Nat Genet 2011, 43:969-976.
• [71]Li T, Li Z, Chen P, Zhao Q, Wang T, Huang K, Li J, Li Y, Liu J, Zeng Z, Feng G, He L, Shi Y: Common Variants in Major Histocompatibility Complex Region and TCF4 Gene Are Significantly Associated with Schizophrenia in Han Chinese. Biol Psychiatry 2010, 68:671-673.
• [72]Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, Salzer JL: GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 1996, 17:229-243.
• [73]Anton ES, Marchionni MA, Lee KF, Rakic P: Role of GGF/neuregulin signaling in interactions between migrating neurons and radial glia in the developing cerebral cortex. Development 1997, 124:3501-3510.
• [74]Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L: Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron 2000, 26:443-455.
• [75]Liu Y, Ford B, Mann MA, Fischbach GD: Neuregulins increase alpha7 nicotinic acetylcholine receptors and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J Neurosci 2001, 21:5660-5669.
• [76]Corfas G, Roy K, Buxbaum JD: Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004, 7:575-580.
• [77]Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71:877-892.
• [78]Pulver AE, Wolyniec PS, Housman D, Kazazian HH, Antonarakis SE, Nestadt G, Lasseter VK, McGrath JA, Dombroski B, Karayiorgou M, Ton C, Blouin JL, Kempf L: The Johns Hopkins University Collaborative Schizophrenia Study: an epidemiologic-genetic approach to test the heterogeneity hypothesis and identify schizophrenia susceptibility genes. Cold Spring Harb Symp Quant Biol 1996, 61:797-814.
• [79]Kendler KS, MacLean CJ, O’Neill FA, Burke J, Murphy B, Duke F, Shinkwin R, Easter SM, Webb BT, Zhang J, Walsh D, Straub RE: Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. Am J Psychiatry 1996, 153:1534-1540.
• [80]Blouin JL, Dombroski BA, Nath SK, Lasseter VK, Wolyniec PS, Nestadt G, Thornquist M, Ullrich G, McGrath J, Kasch L, Lamacz M, Thomas MG, Gehrig C, Radhakrishna U, Snyder SE, Balk KG, Neufeld K, Swartz KL, DeMarchi N, Papadimitriou GN, Dikeos DG, Stefanis CN, Chakravarti A, Childs B, Housman DE, Kazazian HH, Antonarakis S, Pulver AE: Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat Genet 1998, 20:70-73.
• [81]Kaufmann CA, Suarez B, Malaspina D, Pepple J, Svrakic D, Markel PD, Meyer J, Zambuto CT, Schmitt K, Matise TC, Harkavy Friedman JM, Hampe C, Lee H, Shore D, Wynne D, Faraone SV, Tsuang MT, Cloninger CR: NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 1998, 81:282-289.
• [82]Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008, 40:827-834.
• [83]Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, St Clair D: Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003, 72:83-87.
• [84]Williams NM, Preece A, Spurlock G, Norton N, Williams HJ, Zammit S, O’Donovan MC, Owen MJ: Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol Psychiatry 2003, 8:485-487.
• [85]Benzel I, Bansal A, Browning BL, Galwey NW, Maycox PR, McGinnis R, Smart D, St Clair D, Yates P, Purvis I: Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav Brain Funct 2007, 3:31.
• [86]Ikeda M, Takahashi N, Saito S, Aleksic B, Watanabe Y, Nunokawa A, Yamanouchi Y, Kitajima T, Kinoshita Y, Kishi T, Kawashima K, Hashimoto R, Ujike H, Inada T, Someya T, Takeda M, Ozaki N, Iwata N: Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample. Schizophr Res 2008, 101:1-8.
• [87]Alaerts M, Ceulemans S, Forero D, Moens LN, De Zutter S, Heyrman L, Lenaerts A-S, Norrback K-F, De Rijk P, Nilsson L-G, Goossens D, Adolfsson R, Del-Favero J: Support for NRG1 as a susceptibility factor for schizophrenia in a northern Swedish isolated population. Arch Gen Psychiatry 2009, 66:828-837.
• [88]So H-C, Fong PY, Chen RYL, Hui TCK, Ng MYM, Cherny SS, Mak WWM, Cheung EFC, Chan RCK, Chen EYH, Li T, Sham PC: Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:103-113.
• [89]Iwata N, Suzuki T, Ikeda M, Kitajima T, Yamanouchi Y, Inada T, Ozaki N: No association with the neuregulin 1 haplotype to Japanese schizophrenia. Mol Psychiatry 2004, 9:126-127.
• [90]Vilella E, Costas J, Sanjuan J, Guitart M, De Diego Y, Carracedo A, Martorell L, Valero J, Labad A, De Frutos R, Nájera C, Moltó MD, Toirac I, Guillamat R, Brunet A, Vallès V, Pérez L, Leon M, De Fonseca FR, Phillips C, Torres M: Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res 2008, 42:278-288.
• [91]Jungerius BJ, Hoogendoorn MLC, Bakker SC, Van’t Slot R, Bardoel AF, Ophoff RA, Wijmenga C, Kahn RS, Sinke RJ: An association screen of myelin-related genes implicates the chromosome 22q11 PIK4CA gene in schizophrenia. Mol Psychiatry 2008, 13:1060-1068.
• [92]Crowley JJ, Keefe RSE, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF: The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1298-1300.
• [93]Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, Burrell GJ, Rice JP, Nertney DA, Olincy A, Rozic P, Vinogradov S, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Crowe RR, Cloninger CR, Martinez M, Gejman PV: No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 2008, 165:497-506.
• [94]Jönsson EG, Saetre P, Vares M, Andreou D, Larsson K, Timm S, Rasmussen HB, Djurovic S, Melle I, Andreassen OA, Agartz I, Werge T, Hall H, Terenius L: DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association study. Neuropsychobiology 2009, 59:142-150.
• [95]Yang JZ, Si TM, Ruan Y, Ling YS, Han YH, Wang XL, Zhou M, Zhang HY, Kong QM, Liu C, Zhang DR, Yu YQ, Liu SZ, Ju GZ, Shu L, Ma DL, Zhang D: Association study of neuregulin 1 gene with schizophrenia. Mol Psychiatry 2003, 8:706-709.
• [96]Zhao X, Shi Y, Tang J, Tang R, Yu L, Gu N, Feng G, Zhu S, Liu H, Xing Y, Zhao S, Sang H, Guan Y, St Clair D, He L: A case control and family based association study of the neuregulin1 gene and schizophrenia. J Med Genet 2004, 41:31-34.
• [97]Hong C-J, Huo S-J, Liao D-L, Lee K, Wu J-Y, Tsai S-J: Case–control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophrenia. Neurosci Lett 2004, 366:158-161.
• [98]Li T, Stefansson H, Gudfinnsson E, Cai G, Liu X, Murray RM, Steinthorsdottir V, Januel D, Gudnadottir VG, Petursson H, Ingason A, Gulcher JR, Stefansson K, Collier DA: Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 2004, 9:698-704.
• [99]Georgieva L, Dimitrova A, Ivanov D, Nikolov I, Williams NM, Grozeva D, Zaharieva I, Toncheva D, Owen MJ, Kirov G, O’Donovan MC: Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry 2008, 64:419-427.
• [100]Hall D, Gogos JA, Karayiorgou M: The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes Brain Behav 2004, 3:240-248.
• [101]Thiselton DL, Webb BT, Neale BM, Ribble RC, O’Neill FA, Walsh D, Riley BP, Kendler KS: No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). Mol Psychiatry 2004, 9:777-783. image 729
• [102]Turunen JA, Peltonen JO, Pietiläinen OPH, Hennah W, Loukola A, Paunio T, Silander K, Ekelund J, Varilo T, Partonen T, Lönnqvist J, Peltonen L: The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophr Res 2007, 91:27-36.
• [103]Munafò MR, Thiselton DL, Clark TG, Flint J: Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 2006, 11:539-546.
• [104]Munafò MR, Attwood AS, Flint J: Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008, 34:9-12.
• [105]Murphy KC: Schizophrenia and velo-cardio-facial syndrome. Lancet 2002, 359:426-430.
• [106]Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A: A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002, 71:1296-1302.
• [107]St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C, Evans HJ: Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990, 336:13-16.
• [108]Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ: Schizophrenia and affective disorders–cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001, 69:428-433.
• [109]Millar JK, Christie S, Anderson S, Lawson D, Hsiao-Wei Loh D, Devon RS, Arveiler B, Muir WJ, Blackwood DH, Porteous DJ: Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol Psychiatry 2001, 6:173-178.
• [110]Kim JY, Duan X, Liu CY, Jang M-H, Guo JU, Pow-anpongkul N, Kang E, Song H, Ming G: DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 2009, 63:761-773.
• [111]Kato T: Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007, 61:3-19.
• [112]Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, Verchinski BA, Meyer-Lindenberg A, Balkissoon R, Kolachana B, Goldberg TE, Weinberger DR: Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 2005, 102:8627-8632.
• [113]Cannon TD, Hennah W, Van Erp TGM, Thompson PM, Lonnqvist J, Huttunen M, Gasperoni T, Tuulio-Henriksson A, Pirkola T, Toga AW, Kaprio J, Mazziotta J, Peltonen L: Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry 2005, 62:1205-1213.
• [114]Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lönnqvist J, Peltonen L: Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 2004, 9:1037-1041.
• [115]Hennah W, Varilo T, Kestilä M, Paunio T, Arajärvi R, Haukka J, Parker A, Martin R, Levitzky S, Partonen T, Meyer J, Lönnqvist J, Peltonen L, Ekelund J: Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Genet 2003, 12:3151-3159.
• [116]Lepagnol-Bestel A-M, Dubertret C, Benmessaoud D, Simonneau M, Adès J, Kacha F, Hamdani N, Gorwood P, Ramoz N: Association of DISC1 gene with schizophrenia in families from two distinct French and Algerian populations. Psychiatr Genet 2010, 20:298-303.
• [117]Rastogi A, Zai C, Likhodi O, Kennedy JL, Wong AH: Genetic association and post-mortem brain mRNA analysis of DISC1 and related genes in schizophrenia. Schizophr Res 2009, 114:39-49.
• [118]Liu Y-L, Fann CS-J, Liu C-M, Chen WJ, Wu J-Y, Hung S-I, Chen C-H, Jou Y-S, Liu S-K, Hwang T-J, Hsieh MH, Ouyang W-C, Chan H-Y, Chen J-J, Yang W-C, Lin C-Y, Lee SFC, Hwu H-G: A single nucleotide polymorphism fine mapping study of chromosome 1q42.1 reveals the vulnerability genes for schizophrenia, GNPAT and DISC1: Association with impairment of sustained attention. Biol Psychiatry 2006, 60:554-562.
• [119]Hennah W, Thomson P, McQuillin A, Bass N, Loukola A, Anjorin A, Blackwood D, Curtis D, Deary IJ, Harris SE, Isometsä ET, Lawrence J, Lönnqvist J, Muir W, Palotie A, Partonen T, Paunio T, Pylkkö E, Robinson M, Soronen P, Suominen K, Suvisaari J, Thirumalai S, St Clair D, Gurling H, Peltonen L, Porteous D: DISC1 association, heterogeneity and interplay in schizophrenia and bipolar disorder. Mol Psychiatry 2009, 14:865-873.
• [120]Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK: Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004, 75:862-872.
• [121]Mata I, Perez-Iglesias R, Roiz-Santiañez R, Tordesillas-Gutierrez D, Gonzalez-Mandly A, Berja A, Vazquez-Barquero JL, Crespo-Facorro B: Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. Neuroimage 2010, 53:1016-1022.
• [122]Mouaffak F, Kebir O, Chayet M, Tordjman S, Vacheron MN, Millet B, Jaafari N, Bellon A, Olié JP, Krebs M-O: Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. Pharmacogenomics J 2011, 11:267-273.
• [123]Nicodemus KK, Kolachana BS, Vakkalanka R, Straub RE, Giegling I, Egan MF, Rujescu D, Weinberger DR: Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet 2007, 120:889-906.
• [124]Saetre P, Agartz I, De Franciscis A, Lundmark P, Djurovic S, Kähler A, Andreassen OA, Jakobsen KD, Rasmussen HB, Werge T, Hall H, Terenius L, Jönsson EG: Association between a disrupted-in-schizophrenia 1 (DISC1) single nucleotide polymorphism and schizophrenia in a combined Scandinavian case–control sample. Schizophr Res 2008, 106:237-241.
• [125]Schumacher J, Laje G, Abou Jamra R, Becker T, Mühleisen TW, Vasilescu C, Mattheisen M, Herms S, Hoffmann P, Hillmer AM, Georgi A, Herold C, Schulze TG, Propping P, Rietschel M, McMahon FJ, Nöthen MM, Cichon S: The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet 2009, 18:2719-2727.
• [126]Song W, Li W, Feng J, Heston LL, Scaringe WA, Sommer SS: Identification of high risk DISC1 structural variants with a 2% attributable risk for schizophrenia. Biochem Biophys Res Commun 2008, 367:700-706.
• [127]Szeszko PR, Hodgkinson CA, Robinson DG, Derosse P, Bilder RM, Lencz T, Burdick KE, Napolitano B, Betensky JD, Kane JM, Goldman D, Malhotra AK: DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol 2008, 79:103-110.
• [128]Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, Condie A, Muir WJ, Blackwood DHR, Porteous DJ: Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry 2005, 10:657-668. 616
• [129]Wood LS, Pickering EH, Dechairo BM: Significant support for DAO as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia. Biol Psychiatry 2007, 61:1195-1199.
• [130]Zhang F, Sarginson J, Crombie C, Walker N, St Clair D, Shaw D: Genetic association between schizophrenia and the DISC1 gene in the Scottish population. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:155-159.
• [131]Betcheva ET, Mushiroda T, Takahashi A, Kubo M, Karachanak SK, Zaharieva IT, Vazharova RV, Dimova II, Milanova VK, Tolev T, Kirov G, Owen MJ, O’Donovan MC, Kamatani N, Nakamura Y, Toncheva DI: Case–control association study of 59 candidate genes reveals the DRD2 SNP rs6277 (C957T) as the only susceptibility factor for schizophrenia in the Bulgarian population. J Hum Genet 2009, 54:98-107.
• [132]Devon RS, Anderson S, Teague PW, Burgess P, Kipari TM, Semple CA, Millar JK, Muir WJ, Murray V, Pelosi AJ, Blackwood DH, Porteous DJ: Identification of polymorphisms within Disrupted in Schizophrenia 1 and Disrupted in Schizophrenia 2, and an investigation of their association with schizophrenia and bipolar affective disorder. Psychiatr Genet 2001, 11:71-78.
• [133]Crick F: Central dogma of molecular biology. Nature 1970, 227:561-563.
• [134]Pastori C, Wahlestedt C: Involvement of long noncoding RNAs in diseases affecting the central nervous system. RNA Biol 2012, 9:860-870.
• [135]Elgar G, Vavouri T: Tuning in to the signals: noncoding sequence conservation in vertebrate genomes. Trends Genet 2008, 24:344-352.
• [136]Bird A: Perceptions of epigenetics. Nature 2007, 447:396-398.
• [137]Sartor GC, St Laurent G 3rd, Wahlestedt C: The Emerging Role of Non-Coding RNAs in Drug Addiction. Front Genet 2012, 3:106.
• [138]Tsankova N, Renthal W, Kumar A, Nestler EJ: Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007, 8:355-367.
• [139]Nemeroff CB: The burden of severe depression: A review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007, 41:189-206.
• [140]Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9:519-525.
• [141]Meaney MJ, Szyf M: Maternal care as a model for experience-dependent chromatin plasticity? Trends Neurosci 2005, 28:456-463.
• [142]Champagne FA, Francis DD, Mar A, Meaney MJ: Variations in maternal care in the rat as a mediating influence for the effects of environment on development. Physiol Behav 2003, 79:359-371.
• [143]Schroeder M, Krebs MO, Bleich S, Frieling H: Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry 2010, 23:588-592.
• [144]McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonté B, Szyf M, Turecki G, Meaney MJ: Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009, 12:342-348.
• [145]Pollin W, Cardon PV Jr, Kety SS: Effects of amino acid feedings in schizophrenic patients treated with iproniazid. Science 1961, 133:104-105.
• [146]Brune GG, Himwich HE: Effects of methionine loading on the behavior of schizophrenic patients. J Nerv Ment Dis 1962, 134:447-450.
• [147]D’Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T: A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 1995, 374:719-723.
• [148]Abdolmaleky HM, Cheng K-H, Faraone SV, Wilcox M, Glatt SJ, Gao F, Smith CL, Shafa R, Aeali B, Carnevale J, Pan H, Papageorgis P, Ponte JF, Sivaraman V, Tsuang MT, Thiagalingam S: Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet 2006, 15:3132-3145.
• [149]Grayson DR, Chen Y, Costa E, Dong E, Guidotti A, Kundakovic M, Sharma RP: The human reelin gene: transcription factors (+), repressors (−) and the methylation switch (+/−) in schizophrenia. Pharmacol Ther 2006, 111:272-286.
• [150]Abdolmaleky HM, Cheng K, Russo A, Smith CL, Faraone SV, Wilcox M, Shafa R, Glatt SJ, Nguyen G, Ponte JF, Thiagalingam S, Tsuang MT: Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:60-66.
• [151]Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang S-C, Petronis A: Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008, 82:696-711.
• [152]Tochigi M, Iwamoto K, Bundo M, Komori A, Sasaki T, Kato N, Kato T: Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry 2008, 63:530-533.
• [153]Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT: Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004, 67:53-62.
• [154]Abdolmaleky HM, Smith CL, Faraone SV, Shafa R, Stone W, Glatt SJ, Tsuang MT: Methylomics in psychiatry: Modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 2004, 127B:51-59.
• [155]Levinson DF: Meta-analysis in psychiatric genetics. Curr Psychiatry Rep 2005, 7:143-151.
• [156]Polesskaya OO, Aston C, Sokolov BP: Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1. J Neurosci Res 2006, 83:362-373.
• [157]Polesskaya OO, Sokolov BP: Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002, 67:812-822.
• [158]Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS: Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med 2011, 13:66-76.
• [159]Thiagalingam S, Cheng K-H, Lee HJ, Mineva N, Thiagalingam A, Ponte JF: Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003, 983:84-100.
• [160]Sharma RP, Grayson DR, Gavin DP: Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res 2008, 98:111-117.
• [161]Benes FM, Lim B, Matzilevich D, Subburaju S, Walsh JP: Circuitry-based gene expression profiles in GABA cells of the trisynaptic pathway in schizophrenics versus bipolars. Proc Natl Acad Sci USA 2008, 105:20935-20940.
• [162]Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E, DiGiorgi GV: Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000, 57:1061-1069.
• [163]Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM: Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 2002, 59:521-529.
• [164]Woo T-UW, Walsh JP, Benes FM: Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004, 61:649-657.
• [165]Fatemi SH, Hossein Fatemi S, Stary JM, Earle JA, Araghi-Niknam M, Eagan E: GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 2005, 72:109-122.
• [166]Tremolizzo L, Doueiri M-S, Dong E, Grayson DR, Davis J, Pinna G, Tueting P, Rodriguez-Menendez V, Costa E, Guidotti A: Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005, 57:500-509.
• [167]Göttlicher M: Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004, 83:S91-92.
• [168]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [169]Miller BH, Wahlestedt C: MicroRNA dysregulation in psychiatric disease. Brain Res 2010, 1338:89-99.
• [170]Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J, Hammond SM: microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007, 8:R27.
• [171]Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I, Cairns MJ: Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008, 17:1156-1168.
• [172]Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ: Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010, 15:1176-1189.
• [173]Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J, Willoughby D, Kenny PJ, Elsworth JD, Lawrence MS, Roth RH, Edbauer D, Kleiman RJ, Wahlestedt C: MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012, 109:3125-3130.
• [174]Gottesman II, Gould TD: The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003, 160:636-645.
• [175]Beauchaine TP: Role of biomarkers and endophenotypes in prevention and treatment of psychopathological disorders. Biomark Med 2009, 3:1-3.
• [176]Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
• [177]Kraemer HC, Schultz SK, Arndt S: Biomarkers in psychiatry: methodological issues. Am J Geriatr Psychiatry 2002, 10:653-659.
• [178]Wichers M, Myin-Germeys I, Jacobs N, Peeters F, Kenis G, Derom C, Vlietinck R, Delespaul P, Van Os J: Genetic risk of depression and stress-induced negative affect in daily life. Br J Psychiatry 2007, 191:218-223.
• [179]Ellwart T, Rinck M, Becker ES: Selective memory and memory deficits in depressed inpatients. Depress Anxiety 2003, 17:197-206.
• [180]Tarsia M, Power MJ, Sanavio E: Implicit and explicit memory biases in mixed anxiety-depression. J Affect Disord 2003, 77:213-225.
• [181]Erickson K, Drevets WC, Clark L, Cannon DM, Bain EE, Zarate CA Jr, Charney DS, Sahakian BJ: Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry 2005, 162:2171-2173.
• [182]Koster EHW, De Raedt R, Leyman L, De Lissnyder E: Mood-congruent attention and memory bias in dysphoria: Exploring the coherence among information-processing biases. Behav Res Ther 2010, 48:219-225.
• [183]Van Wingen GA, Van Eijndhoven P, Cremers HR, Tendolkar I, Verkes RJ, Buitelaar JK, Fernández G: Neural state and trait bases of mood-incongruent memory formation and retrieval in first-episode major depression. J Psychiatr Res 2010, 44:527-534.
• [184]Dryman A, Eaton WW: Affective symptoms associated with the onset of major depression in the community: findings from the US National Institute of Mental Health Epidemiologic Catchment Area Program. Acta Psychiatr Scand 1991, 84:1-5.
• [185]Hirschfeld RM, Klerman GL, Clayton PJ, Keller MB: Personality and depression. Empirical findings. Arch Gen Psychiatry 1983, 40:993-998.
• [186]Schrader GD: Does anhedonia correlate with depression severity in chronic depression? Compr Psychiatry 1997, 38:260-263.
• [187]Hecht H, Van Calker D, Berger M, Von Zerssen D: Personality in patients with affective disorders and their relatives. J Affect Disord 1998, 51:33-43.
• [188]McCabe C, Cowen PJ, Harmer CJ: Neural representation of reward in recovered depressed patients. Psychopharmacology (Berl) 2009, 205:667-677.
• [189]Lester D: The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 1995, 28:45-50.
• [190]Galfalvy H, Currier D, Oquendo MA, Sullivan G, Huang Y-Y, John Mann J: Lower CSF MHPG predicts short-term risk for suicide attempt. Int J Neuropsychopharmacol 2009, 12:1327-1335.
• [191]Ramel W, Goldin PR, Eyler LT, Brown GG, Gotlib IH, McQuaid JR: Amygdala reactivity and mood-congruent memory in individuals at risk for depressive relapse. Biol Psychiatry 2007, 61:231-239.
• [192]Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001, 2:24-32.
• [193]Autry AE, Monteggia LM: Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012, 64:238-258.
• [194]Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry J-M, Bertschy G: Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005, 57:1068-1072.
• [195]Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ: Transport of brain-derived neurotrophic factor across the blood–brain barrier. Neuropharmacology 1998, 37:1553-1561.
• [196]Fernandes BS, Gama CS, Ceresér KM, Yatham LN, Fries GR, Colpo G, De Lucena D, Kunz M, Gomes FA, Kapczinski F: Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
• [197]Lin P-Y: State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009, 466:139-143.
• [198]Fernandes BS, Gama CS, Kauer-Sant’Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F: Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res 2009, 43:1200-1204.
• [199]Wehr TA, Goodwin FK: Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987, 144:1403-1411.
• [200]Bora E, Yucel M, Pantelis C: Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009, 113:1-20.
• [201]Snitz BE, Macdonald AW 3rd, Carter CS: Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006, 32:179-194.
• [202]Gur RE, Nimgaonkar VL, Almasy L, Calkins ME, Ragland JD, Pogue-Geile MF, Kanes S, Blangero J, Gur RC: Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry 2007, 164:813-819.
• [203]Sitskoorn MM, Aleman A, Ebisch SJH, Appels MCM, Kahn RS: Cognitive deficits in relatives of patients with schizophrenia: a meta-analysis. Schizophr Res 2004, 71:285-295.
• [204]Szöke A, Schürhoff F, Mathieu F, Meary A, Ionescu S, Leboyer M: Tests of executive functions in first-degree relatives of schizophrenic patients: a meta-analysis. Psychol Med 2005, 35:771-782.
• [205]Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare L: A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 2005, 15:73-95.
• [206]Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P: Neuropsychological function in schizophrenia, Selective impairment in memory and learning. Arch Gen Psychiatry 1991, 48:618-624.
• [207]Egan MF, Goldberg TE, Gscheidle T, Weirich M, Rawlings R, Hyde TM, Bigelow L, Weinberger DR: Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry 2001, 50:98-107.
• [208]Cannon TD, Zorrilla LE, Shtasel D, Gur RE, Gur RC, Marco EJ, Moberg P, Price RA: Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry 1994, 51:651-661.
• [209]Faraone SV, Seidman LJ, Kremen WS, Pepple JR, Lyons MJ, Tsuang MT: Neuropsychological functioning among the nonpsychotic relatives of schizophrenic patients: a diagnostic efficiency analysis. J Abnorm Psychol 1995, 104:286-304.
• [210]Conklin HM, Curtis CE, Calkins ME, Iacono WG: Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 2005, 43:930-942.
• [211]Gibbons JL, McHugh PR: Plasma cortisol in depressive illness. J Psychiatr Res 1962, 1:162-171.
• [212]Carpenter WT Jr, Bunney WE Jr: Adrenal cortical activity in depressive illness. Am J Psychiatry 1971, 128:31-40.
• [213]Swanson LW, Sawchenko PE, Rivier J, Vale WW: Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983, 36:165-186.
• [214]Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160:1-12.
• [215]Dunn AJ, Berridge CW: Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990, 15:71-100.
• [216]Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991, 43:425-473.
• [217]Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, Gillespie CF, Berg T, Evces M, Newport DJ, Stowe ZN, Heim CM, Nemeroff CB, Schwartz A, Cubells JF, Ressler KJ: Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 2008, 65:190-200.
• [218]Polanczyk G, Caspi A, Williams B, Price TS, Danese A, Sugden K, Uher R, Poulton R, Moffitt TE: Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry 2009, 66:978-985.
• [219]Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL: Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry 2009, 66:681-685.
• [220]Heim C, Bradley B, Mletzko TC, Deveau TC, Musselman DL, Nemeroff CB, Ressler KJ, Binder EB: Effect of Childhood Trauma on Adult Depression and Neuroendocrine Function: Sex-Specific Moderation by CRH Receptor 1 Gene. Front Behav Neurosci 2009, 3:41.
• [221]Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
• [222]McGuffin P, Asherson P, Owen M, Farmer A: The strength of the genetic effect. Is there room for an environmental influence in the aetiology of schizophrenia? Br J Psychiatry 1994, 164:593-599.
• [223]Stabenau JR, Pollin W: Early characteristics of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1967, 17:723-734.
• [224]Cannon M, Jones PB, Murray RM: Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 2002, 159:1080-1092.
• [225]Scott J, McNeill Y, Cavanagh J, Cannon M, Murray R: Exposure to obstetric complications and subsequent development of bipolar disorder: Systematic review. Br J Psychiatry 2006, 189:3-11.
• [226]Mednick SA, Machon RA, Huttunen MO, Bonett D: Adult schizophrenia following prenatal exposure to an influenza epidemic. Arch Gen Psychiatry 1988, 45:189-192.
• [227]O’Callaghan E, Sham P, Takei N, Glover G, Murray RM: Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Lancet 1991, 337:1248-1250.
• [228]Brown AS: Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006, 32:200-202.
• [229]Selten J-P, Frissen A, Lensvelt-Mulders G, Morgan VA: Schizophrenia and 1957 pandemic of influenza: meta-analysis. Schizophr Bull 2010, 36:219-228.
• [230]Selten J-P, Cantor-Graae E, Nahon D, Levav I, Aleman A, Kahn RS: No relationship between risk of schizophrenia and prenatal exposure to stress during the Six-Day War or Yom Kippur War in Israel. Schizophr Res 2003, 63:131-135.
• [231]Ferguson CS, Tyndale RF: Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 2011, 32:708-714.
• [232]Stingl JC, Brockmöller J, Viviani R: Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2013, 18:273-287.
• [233]Bromek E, Haduch A, Gołembiowska K, Daniel WA: Cytochrome P450 mediates dopamine formation in the brain in vivo. J Neurochem 2011, 118:806-815.
• [234]Yu A-M, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003, 13:173-181.
• [235]Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996, 153:311-320.
• [236]Thakur M, Grossman I, McCrory DC, Orlando LA, Steffens DC, Cline KE, Gray RN, Farmer J, DeJesus G, O’Brien C, Samsa G, Goldstein DB, Matchar DB: Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007, 9:826-835.
• [237]Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, De Warren-Penny P, Dickson R: The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 2010, 14:1-157. iii
• [238]Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, Pirmohamed M, Walley T: Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011, 11:1-14.
• [239]Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A: Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011, 36:87-113.
• [240]Mrazek DA, Rush AJ, Biernacka JM, O’Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL 3rd, Weinshilboum RM: SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:341-351.
• [241]Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X: Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 2009, 205:409-417.
• [242]Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D, Placentino A, Zobel A, Larsen ER, Czerski PM, Gupta B, Hoda F, Perroud N, Farmer A, Craig I, Aitchison KJ, McGuffin P: Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009, 195:30-38.
• [243]Bozina N, Peles AM, Sagud M, Bilusic H, Jakovljevic M: Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 2008, 9:190-197.
• [244]Smeraldi E, Serretti A, Artioli P, Lorenzi C, Catalano M: Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet 2006, 16:153-158.
• [245]Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511.
• [246]Hong C-J, Chen T-J, Yu YW-Y, Tsai S-J: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006, 6:27-33.
• [247]Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, Yamashita M, Takekita Y, Nobuhara K, Azuma J, Kinoshita T: Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
• [248]Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, Fukuda K, Azuma J, Kinoshita T: Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005, 20:151-156.
• [249]Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, Hobby HM, Ganapathy V, Leibach FH: Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002, 51:723-732.
• [250]Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E: Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001, 50:323-330.
• [251]Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R: Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004, 129B:36-40.
• [252]Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004, 61:1163-1169.
• [253]Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, Van Os J, Prins M: Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007, 22:137-143.
• [254]Smits KM, Smits LJM, Peeters FPML, Schouten JSAG, Janssen RGJH, Smeets HJM, Van Os J, Prins MH: The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008, 18:184-190.
• [255]Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004, 174:525-529.
• [256]Arias B, Catalán R, Gastó C, Gutiérrez B, Fañanás L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003, 23:563-567.
• [257]Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003, 6:339-346.
• [258]Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
• [259]Kim H, Lim S-W, Kim S, Kim J-W, Chang YH, Carroll BJ, Kim DK: Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006, 296:1609-1618.
• [260]Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, Naito S, Shimizu T, Itoh K, Inoue K, Suzuki T, Nemeroff CB: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004, 161:1575-1580.
• [261]Lotrich FE, Pollock BG, Kirshner M, Ferrell RF: Reynolds Iii CF: Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008, 33:123-130.
• [262]Yoshimura R, Umene-Nakano W, Suzuki A, Ueda N, Miyamoto K, Ikenouchi-Sugita A, Hori H, Otani K, Nakamura J: Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 2009, 24:489-494.
• [263]Ng CH, Easteal S, Tan S, Schweitzer I, Ho BKW, Aziz S: Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:953-957.
• [264]Yu YW-Y, Tsai S-J, Liou Y-J, Hong C-J, Chen T-J: Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006, 16:498-503.
• [265]Serretti A, Artioli P, Lorenzi C, Pirovano A, Tubazio V, Zanardi R: The C(−1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004, 7:453-460.
• [266]Kato M, Fukuda T, Wakeno M, Okugawa G, Takekita Y, Watanabe S, Yamashita M, Hosoi Y, Azuma J, Kinoshita T, Serretti A: Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:115-123.
• [267]Levin GM, Bowles TM, Ehret MJ, Langaee T, Tan JY, Johnson JA, Millard WJ: Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007, 11:155-160.
• [268]Suzuki Y, Sawamura K, Someya T: Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006, 31:825-831.
• [269]Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004, 9:879-889.
• [270]Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, Maier W, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, Zobel A, Czerski PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I: Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009, 9:225-233.
• [271]Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP: Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009, 19:1-10.
• [272]Wilkie MJV, Smith G, Day RK, Matthews K, Smith D, Blackwood D, Reid IC, Wolf CR: Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009, 9:61-70.
• [273]McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJM, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:804-814.
• [274]Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003, 160:1830-1835.
• [275]Illi A, Setälä-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimäki T, Leinonen E, Kampman O: 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20:1125-1128.
• [276]Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N, Haraguchi K, Ieiri I, Kinukawa N, Hosoi M, Ohtani H, Sawada Y, Mine K: Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008, 11:261-267.
• [277]Sato K, Yoshida K, Takahashi H, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46:136-140.
• [278]Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ: Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 2008, 299:1291-1305.
• [279]Velders FP, Kuningas M, Kumari M, Dekker MJ, Uitterlinden AG, Kirschbaum C, Hek K, Hofman A, Verhulst FC, Kivimaki M, Van Duijn CM, Walker BR, Tiemeier H: Genetics of cortisol secretion and depressive symptoms: a candidate gene and genome wide association approach. Psychoneuroendocrinology 2011, 36:1053-1061.
• [280]Kang JI, Chung HC, Jeung H-C, Kim SJ, An SK, Namkoong K: FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study. Psychoneuroendocrinology 2012, 37:1569-1576.
• [281]Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB: Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 2010, 67:369-379.
• [282]Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, Von Zastrow M, Slager SL, Hamilton SP: Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry 2010, 167:565-573.
• [283]Laje G, Allen AS, Akula N, Manji H, John Rush A, McMahon FJ: Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009, 19:666-674.
• [284]Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP: A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
• [285]Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, Kohli MA, Hennings JM, Horstmann S, Kloiber S, Menke A, Bondy B, Rupprecht R, Domschke K, Baune BT, Arolt V, Rush AJ, Holsboer F, Müller-Myhsok B: A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009, 66:966-975.
• [286]Malhotra AK: The Pharmacogenetics of Depression: Enter the GWAS. Am J Psychiatry 2010, 167:493-495.
• [287]Rybakowski JK, Suwalska A, Czerski PM, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005, 57:124-127.
• [288]Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, Kunugi H, Koyama T: A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006, 9:83-88.
• [289]Benedetti F, Dallaspezia S, Fulgosi MC, Lorenzi C, Serretti A, Barbini B, Colombo C, Smeraldi E: Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:631-635.
• [290]Rybakowski JK, Suwalska A, Skibinska M, Dmitrzak-Weglarz M, Leszczynska-Rodziewicz A, Hauser J: Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:820-823.
• [291]Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M: Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 2007, 62:1295-1302.
• [292]Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S, Suzuki T, Iwata N, Ozaki N, Kato T, Takeda M, Kunugi H, Koyama T: A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:204-208.
• [293]Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G: Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:500-504.
• [294]Dmitrzak-Weglarz M, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Szczepankiewicz A, Hauser J: Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008, 9:1595-1603.
• [295]Arranz MJ, De Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007, 12:707-747.
• [296]Foster A, Miller DD, Buckley PF: Pharmacogenetics and schizophrenia. Psychiatr Clin North Am 2007, 30:417-435.
• [297]Nnadi CU, Malhotra AK: Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep 2007, 9:313-318.
• [298]Reynolds GP: The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discov Today 2007, 12:953-959.
• [299]Thelma B, Srivastava V, Tiwari AK: Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008, 9:1285-1306.
• [300]Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Müller DJ, King N, Voineskos AN, Meltzer HY, Lieberman JA, Potkin SG, Remington G, Kennedy JL: Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008, 106:248-252.
• [301]Steen VM, Løvlie R, MacEwan T, McCreadie RG: Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997, 2:139-145.
• [302]Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002, 27:105-119.
• [303]Woo S, Kim JW, Rha E, Han S, Hahn K, Park C, Sohn J: Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002, 56:469-474.
• [304]Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
• [305]Tsai H-T, North KE, West SL, Poole C: The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:57-66.
• [306]Bakker PR, Van Harten PN, Van Os J: Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13:544-556.
• [307]Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, Nakamura J: Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
• [308]Hitzeroth A, Niehaus DJH, Koen L, Botes WC, Deleuze JF, Warnich L: Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:664-672.
• [309]Kang S-G, Choi J-E, An H, Park Y-M, Lee H-J, Han C, Kim Y-K, Kim S-H, Cho SN, Joe S-H, Jung I-K, Kim L, Lee M-S: Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1844-1847.
• [310]Lerer B, Segman RH, Tan E-C, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong S-A, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F: Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005, 8:411-425.
• [311]Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL: Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:50-56.
• [312]Boke O, Gunes S, Kara N, Aker S, Sahin AR, Basar Y, Bagci H: Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA Cell Biol 2007, 26:527-531.
• [313]Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
• [314]Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000, 157:975-981.
• [315]Müller DJ, Kennedy JL: Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7:863-887.
• [316]Ryu S, Cho EY, Park T, Oh S, Jang W-S, Kim S-K, Lee D, Hong KS: 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:673-677.
• [317]Templeman LA, Reynolds GP, Arranz B, San L: Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200.
• [318]Reynolds GP: The pharmacogenetics of symptom response to antipsychotic drugs. Psychiatry Investig 2012, 9:1-7.
• [319]Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q, Shen Y, Kosten TA, Kosten TR: Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007, 27:246-251.
• [320]De Luca V, Mueller DJ, De Bartolomeis A, Kennedy JL: Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007, 10:697-704.
• [321]Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ: Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010, 11:1561-1571.
• [322]Opgen-Rhein C, Brandl EJ, Müller DJ, Neuhaus AH, Tiwari AK, Sander T, Dettling M: Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010, 11:773-780.
• [323]Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic, A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
• [324]Alvir JM, Lieberman JA: A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994, 14:87-89.
• [325]Chowdhury NI, Remington G, Kennedy JL: Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011, 13:156-165.
• [326]Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR: Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011, 72:458-463.
• [327]Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R: Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007, 7:325-332.
• [328]Need AC, Keefe RSE, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB: Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009, 17:946-957.
• [329]McClay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, Van den Oord EJCG: Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011, 16:76-85.
• [330]Huffaker SJ, Chen J, Nicodemus KK, Sambataro F, Yang F, Mattay V, Lipska BK, Hyde TM, Song J, Rujescu D, Giegling I, Mayilyan K, Proust MJ, Soghoyan A, Caforio G, Callicott JH, Bertolino A, Meyer-Lindenberg A, Chang J, Ji Y, Egan MF, Goldberg TE, Kleinman JE, Lu B, Weinberger DR: A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nat Med 2009, 15:509-518.
• [331]Kongsamut S, Kang J, Chen X-L, Roehr J, Rampe D: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002, 450:37-41.
• [332]Apud JA, Zhang F, Decot H, Bigos KL, Weinberger DR: Genetic variation in KCNH2 associated with expression in the brain of a unique hERG isoform modulates treatment response in patients with schizophrenia. Am J Psychiatry 2012, 169:725-734.
• [333]Zhang J-P, Lencz T, Malhotra AK: D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167:763-772.
• [334]Hwang R, Zai C, Tiwari A, Müller DJ, Arranz MJ, Morris AG, McKenna PJ, Munro J, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL: Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010, 10:200-218.
• [335]Schäfer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Möller HJ: Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001, 158:802-804.
• [336]Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O’Donovan MC, Nakamura J, Ozaki N, Iwata N: Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
• [337]Shen Y-C, Chen S-F, Chen C-H, Lin CCH, Chen S-J, Chen Y-J, Luu S-U: Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009, 43:600-606.
• [338]Jönsson EG, Flyckt L, Burgert E, Crocq M-A, Forslund K, Mattila-Evenden M, Rylander G, Asberg M, Nimgaonkar VL, Edman G, Bjerkenstedt L, Wiesel F-A, Sedvall GC: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr Genet 2003, 13:1-12.
• [339]Binder EB, Nemeroff CB: Implications for the practice of psychiatry. Progress in Brain Research 2006, 158:275-293.
• [340]De Leon J: Pharmacogenomics: The Promise of Personalized Medicine for CNS Disorders. Neuropsychopharmacology 2008, 34:159-172.
• [341]Bogdan R, Hyde LW, Hariri AR: A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. Mol Psychiatry 2012, 18:288-299.
• [342]Hanlon CA, Jones EM, Li X, Hartwell KJ, Brady KT, George MS: Individual variability in the locus of prefrontal craving for nicotine: Implications for brain stimulation studies and treatments. Drug Alcohol Depend 2012, 125:239-243.
• [343]Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH: Functional Neuroimaging of Major Depressive Disorder: A Meta-Analysis and New Integration of Baseline Activation and Neural Response Data. Am J Psychiatry 2012, 169:693-703.
• [344]Johnson JS, Hamidi M, Postle BR: Using EEG to explore how rTMS produces its effects on behavior. Brain Topogr 2010, 22:281-293.
• [345]Etkin A, Wager TD: Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry 2007, 164:1476-1488.
• [346]Frodl T, Möller H-J, Meisenzahl E: Neuroimaging genetics: new perspectives in research on major depression? Acta Psychiatr Scand 2008, 118:363-372.
• [347]Thompson PM, Martin NG, Wright MJ: Imaging genomics. Curr Opin Neurol 2010, 23:368-373.
• [348]Marano CM, Workman CI, Kramer E, Hermann CR, Ma Y, Dhawan V, Chaly T, Eidelberg D, Smith GS: Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. Int J Geriatr Psychiatry 2013, 28:417-423.
• [349]Neumeister A, Normandin MD, Murrough JW, Henry S, Bailey CR, Luckenbaugh DA, Tuit K, Zheng M-Q, Galatzer-Levy IR, Sinha R, Carson RE, Potenza MN, Huang Y: Positron Emission Tomography Shows Elevated Cannabinoid CB (1) Receptor Binding in Men with Alcohol Dependence. Alcohol Clin Exp Res 2012, 36:2104-2109.
• [350]Nord M, Farde L: Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 2011, 17:97-103.
• [351]Steele JD, Currie J, Lawrie SM, Reid I: Prefrontal cortical functional abnormality in major depressive disorder: a stereotactic meta-analysis. J Affect Disord 2007, 101:1-11.
• [352]Campbell S, Marriott M, Nahmias C, MacQueen GM: Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004, 161:598-607.
• [353]Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 2004, 161:1957-1966.
• [354]Sheline YI, Gado MH, Kraemer HC: Untreated depression and hippocampal volume loss. Am J Psychiatry 2003, 160:1516-1518.
• [355]Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C, Kugel H, Arolt V, Heindel W, Kersting A, Baune BT, Suslow T: 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 2008, 33:418-424.
• [356]Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, Kersting A, Arolt V, Heindel W, Deckert J, Suslow T: Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav 2007, 6:672-676.
• [357]Frodl T, Meisenzahl EM, Zill P, Baghai T, Rujescu D, Leinsinger G, Bottlender R, Schüle C, Zwanzger P, Engel RR, Rupprecht R, Bondy B, Reiser M, Möller H-J: Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 2004, 61:177-183.
• [358]Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK, Krishnan KRR: Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 2005, 62:537-544.
• [359]McDonald C, Zanelli J, Rabe-Hesketh S, Ellison-Wright I, Sham P, Kalidindi S, Murray RM, Kennedy N: Meta-analysis of magnetic resonance imaging brain morphometry studies in bipolar disorder. Biol Psychiatry 2004, 56:411-417.
• [360]Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM: Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008, 65:1017-1032.
• [361]Vita A, De Peri L, Sacchetti E: Gray matter, white matter, brain, and intracranial volumes in first-episode bipolar disorder: a meta-analysis of magnetic resonance imaging studies. Bipolar Disord 2009, 11:807-814.
• [362]Beyer JL, Young R, Kuchibhatla M, Krishnan KRR: Hyperintense MRI lesions in bipolar disorder: A meta-analysis and review. Int Rev Psychiatry 2009, 21:394-409.
• [363]Kempton MJ, Salvador Z, Munafò MR, Geddes JR, Simmons A, Frangou S, Williams SCR: Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011, 68:675-690.
• [364]Houenou J, Frommberger J, Carde S, Glasbrenner M, Diener C, Leboyer M, Wessa M: Neuroimaging-based markers of bipolar disorder: evidence from two meta-analyses. J Affect Disord 2011, 132:344-355.
• [365]Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Höschl C: Amygdala volumes in mood disorders–meta-analysis of magnetic resonance volumetry studies. J Affect Disord 2009, 115:395-410.
• [366]Pfeifer JC, Welge J, Strakowski SM, Adler CM, DelBello MP: Meta-analysis of amygdala volumes in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2008, 47:1289-1298.
• [367]Davidson LL, Heinrichs RW: Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res 2003, 122:69-87.
• [368]Hill K, Mann L, Laws KR, Stephenson CME, Nimmo-Smith I, McKenna PJ: Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand 2004, 110:243-256.
• [369]Raz S, Raz N: Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. Psychol Bull 1990, 108:93-108.
• [370]Boos HBM, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS: Brain volumes in relatives of patients with schizophrenia: a meta-analysis. Arch Gen Psychiatry 2007, 64:297-304.
• [371]Zakzanis KK, Hansen KT: Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998, 32:201-206.
• [372]Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM: Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry 2011, 70:88-96.
• [373]Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ: Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012, 36:1342-1356.
• [374]Nelson MD, Saykin AJ, Flashman LA, Riordan HJ: Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 1998, 55:433-440.
• [375]Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA: Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006, 188:510-518.
• [376]Adriano F, Caltagirone C, Spalletta G: Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 2012, 18:180-200.
• [377]Baig BJ, Whalley HC, Hall J, McIntosh AM, Job DE, Cunningham-Owens DG, Johnstone EC, Lawrie SM: Functional magnetic resonance imaging of BDNF val66met polymorphism in unmedicated subjects at high genetic risk of schizophrenia performing a verbal memory task. Psychiatry Res 2010, 183:195-201.
• [378]Van Zuiden M, Geuze E, Willemen HLDM, Vermetten E, Maas M, Heijnen CJ, Kavelaars A: Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. Am J Psychiatry 2011, 168:89-96.
• [379]Gatt JM, Williams LM, Schofield PR, Dobson-Stone C, Paul RH, Grieve SM, Clark CR, Gordon E, Nemeroff CB: Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. Depress Anxiety 2010, 27:752-759.
• [380]Murphy KC, Jones LA, Owen MJ: High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999, 56:940-945.
• [381]Dunbar L, Butler R, Wheeler A, Pulford J, Miles W, Sheridan J: Clinician experiences of employing the AmpliChip® CYP450 test in routine psychiatric practice. J Psychopharmacol (Oxford) 2012, 26:390-397.